Terbinafine Safety Profile

Known Side Effects of Terbinafine

• The British Association of Dermatologists recommends monitoring for gastrointestinal disturbances, including nausea, diarrhea, and taste disturbance, which occur in 49% of reported side effects 1, 2
• The British Association of Dermatologists notes that dermatological events, such as rash, pruritus, urticaria, and eczema, occur in 23% of reported side effects 1, 2
• Rare serious adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, can occur in patients taking terbinafine 1, 2
• The British Association of Dermatologists warns of rare hepatic toxicity, particularly in patients with pre-existing liver disease 1, 2
• A very rare taste disturbance that can potentially be permanent has been reported in patients taking terbinafine 1, 2

Clinical Monitoring Recommendations

• The British Association of Dermatologists recommends baseline liver function tests and complete blood count in patients with a history of heavy alcohol consumption, hepatitis, hematological abnormalities, or in children, as terbinafine is not licensed for pediatric onychomycosis 1, 2
• Monitoring for drug interactions, particularly with medications metabolized by cytochrome P450 2D6 isoenzyme, is recommended when prescribing terbinafine 1, 2
• The British Association of Dermatologists advises avoiding use in patients with active or chronic liver disease 1, 2

Pharmacokinetics and Safety

• The British Association of Dermatologists notes that terbinafine is primarily cleared by the kidney, and its clearance is decreased in patients with severe kidney disease 1, 2

Terbinafine and Renal Function Guidelines

Introduction to Terbinafine Use

• The British Association of Dermatologists recommends that terbinafine is contraindicated in patients with renal impairment, as it can affect renal function 3, 4

Renal Considerations

• The British Association of Dermatologists explicitly lists renal impairment as a contraindication for terbinafine use, as it is primarily cleared by the kidneys 3, 4

Monitoring and Alternative Treatments

• In patients with pre-existing renal disease, alternative antifungal medications should be considered, such as itraconazole for patients with normal hepatic function 3, 4
• For patients requiring antifungal therapy who have renal impairment, topical treatments like amorolfine or ciclopirox may be safer alternatives 3, 4

Treatment Initiation and Adjustment

• Terbinafine is specifically contraindicated rather than recommended for adjusted dosing in patients with reduced renal function, unlike some medications where dose adjustments can compensate for reduced renal function 3, 4

Terbinafine Use in Chronic Kidney Disease

Introduction to Terbinafine Contraindications

• The British Association of Dermatologists explicitly lists renal impairment as a contraindication for terbinafine, as it is primarily cleared by the kidneys, in patients with creatinine clearance ≤50 mL/min 5

Alternative Treatment Options for CKD Patients

• For patients with CKD requiring antifungal therapy for onychomycosis, topical treatments are the preferred approach, including amorolfine 5% lacquer applied once or twice weekly for 6-12 months, and ciclopirox 8% lacquer applied once daily for up to 48 weeks, as recommended by the British Association of Dermatologists 5
• If systemic therapy is absolutely necessary and hepatic function is normal, itraconazole may be considered as an alternative, though it also requires dose adjustment when creatinine clearance <30 mL/min, according to the American Journal of Kidney Diseases and the British Journal of Dermatology 5, 6
• Fluconazole requires 50% dose reduction when GFR <45 mL/min and is contraindicated in severe renal impairment, as stated by the American Journal of Kidney Diseases and the British Journal of Dermatologists 5, 6

Clinical Decision Algorithm for CKD Patients

• For CrCl ≤50 mL/min, select alternative therapy, with first choice being topical therapy (amorolfine or ciclopirox), and second choice being itraconazole if hepatic function is normal and systemic therapy is essential, as recommended by the British Association of Dermatologists 5

Critical Monitoring Considerations for CKD Patients

• The KDIGO guidelines emphasize that medications requiring renal dose adjustment should be calculated using online or electronic calculators to prevent dosing errors, as stated by the American Journal of Kidney Diseases 6

Terbinafine Liver Monitoring Guidelines

Baseline Testing and Monitoring Requirements

• The British Association of Dermatologists recommends obtaining complete blood count alongside baseline liver function tests (LFTs) before prescribing terbinafine, particularly for patients without risk factors 7, 8
• Baseline LFTs, including serum transaminases (ALT and AST), should be measured before starting terbinafine therapy, according to the British Journal of Dermatology guidelines 7, 8

Risk-Stratified Monitoring Approach

• The British Association of Dermatologists recommends monitoring hepatic function tests during terbinafine therapy, particularly if treatment extends beyond one month, for high-risk patients with a history of liver disease or other risk factors 7, 9
• High-risk patients, including those with prior hepatitis or known liver disease, should be closely monitored during terbinafine treatment, as recommended by the British Association of Dermatologists 7, 9

Alternative Agents for High-Risk Patients

• The British Association of Dermatologists suggests considering alternative agents, such as itraconazole or fluconazole, for high-risk patients who require systemic therapy but may be at excessive risk with terbinafine 7, 8, 9
• Topical therapy, such as amorolfine 5% lacquer or ciclopirox 8% lacquer, may be sufficient for some patients and can be considered as an alternative to terbinafine, according to the British Association of Dermatologists 7, 9

Terbinafine Adverse Effects and Clinical Considerations

Adverse Effect Profile

• The American Academy of Pediatrics notes that hepatotoxicity, particularly in patients with pre-existing liver disease, is a serious but rare adverse effect of terbinafine 10
• The American Academy of Pediatrics also reports that rare hematologic effects, including occasional isolated neutropenia, can occur with terbinafine use 10

Clinical Interpretation and Recommendations

• The Infectious Diseases Society of America and the American Academy of Pediatrics suggest that if a patient on terbinafine presents with leg pain, alternative etiologies should be investigated rather than attributing it to the medication 10, 11
• The American Academy of Pediatrics recommends evaluating for other causes of leg pain, such as vascular, neurologic, orthopedic, or infectious causes, in patients taking terbinafine who experience leg pain 10
• The American Academy of Pediatrics also suggests considering whether the underlying fungal infection itself could be causing discomfort in patients taking terbinafine who experience leg pain 10

Monitoring Liver Function in Patients Taking Terbinafine

Baseline and Ongoing Monitoring

• The British Association of Dermatologists recommends monitoring hepatic function tests in patients receiving continuous terbinafine therapy for more than a month, particularly in low-risk patients with normal baseline liver tests 12, 13
• For low-risk patients with normal baseline liver tests, routine periodic monitoring of liver function tests is not required unless treatment extends beyond one month or clinical symptoms develop, as per the British Association of Dermatologists guidelines 12, 14
• The British Association of Dermatologists suggests that treatment duration of ≤4 weeks (fingernail infection) or ≤12 weeks (toenail infection) does not require repeat LFTs during the standard treatment course, unless clinical symptoms develop 12, 14
• Patients taking concomitant hepatotoxic medications should be monitored more closely, as recommended by the British Association of Dermatologists 12, 13
• Discontinue terbinafine immediately if biochemical evidence of liver injury or clinical symptoms of hepatotoxicity develop, such as progressive skin rash, as advised by the British Journal of Dermatology 14

Special Considerations

• The British Association of Dermatologists recommends monitoring patients with pre-existing liver function abnormalities, history of heavy alcohol consumption, history of hepatitis, or hematological abnormalities more closely while on terbinafine therapy 12, 13

Terbinafine Use in Patients with Controlled Hepatitis B on Entecavir

Baseline Assessment Requirements

• Baseline liver function tests (ALT, AST, bilirubin) should be obtained to confirm normal values before initiating terbinafine therapy, as recommended by the British Journal of Dermatology (2014). 15

Terbinafine Treatment Protocol

• For severe toenail onychomycosis, terbinafine 250 mg orally once daily for 12–16 weeks is the recommended regimen (British Journal of Dermatology, 2014). 15

Alternative Systemic Therapy

• Itraconazole 200 mg daily for 12 weeks continuously, or a pulse regimen of 400 mg daily for 1 week per month for three pulses, provides a comparable hepatotoxicity profile and may be considered when terbinafine is of concern (British Journal of Dermatology, 2014). 15

Clinical Decision Guidance

• In patients with virologically suppressed hepatitis B and normal transaminases, terbinafine remains the first‑line systemic option for dermatophyte onychomycosis, provided that patients are counseled about the heightened risk of hepatotoxicity (British Journal of Dermatology, 2014). 15

Monitoring and Management of Hepatotoxicity in High‑Risk Patients Treated with Oral Terbinafine

Monitoring Schedule for High‑Risk Patients

• For patients with risk factors (e.g., heavy alcohol use, prior liver disease, concurrent hepatotoxic drugs), obtain baseline liver function tests and then perform weekly LFTs for the first two weeks, followed by testing every two weeks for the first two months of therapy. This schedule is adapted from chronic‑liver‑disease guidelines used in tuberculosis treatment and represents a conservative approach when systemic antifungal therapy cannot be avoided. 16

Patient‑Education and Symptom‑Driven Action

• Patients (and their primary‑care physicians) should be instructed to stop terbinafine immediately and seek medical attention if they develop any of the following symptoms: jaundice or dark urine, persistent nausea, vomiting, or abdominal pain, unexplained fatigue or malaise, severe or progressive skin rash, or pruritus. Prompt discontinuation is crucial because symptomatic presentation typically precedes detectable laboratory abnormalities. 16

Management of Abnormal Baseline LFTs

Baseline AST/ALT < 2 × Upper Limit of Normal (ULN)

• Repeat LFTs at 2 weeks after initiation. 16
• If transaminases have decreased, further testing is required only if clinical symptoms develop. 16
• If the repeat test shows AST/ALT ≥ 2 × ULN, escalate to weekly monitoring. 16

Baseline AST/ALT ≥ 2 × ULN

• Monitor weekly for the first 2 weeks, then every two weeks until values return to normal. 16

AST/ALT ≥ 5 × ULN or Rising Bilirubin During Treatment

• Discontinue terbinafine immediately. 16